UA76475C2 - Combination of eplerenon and hmg co-a reductase inhibitor and its use for treatment and/or prophylaxis of pathologic condition in cardiovascular system - Google Patents

Combination of eplerenon and hmg co-a reductase inhibitor and its use for treatment and/or prophylaxis of pathologic condition in cardiovascular system Download PDF

Info

Publication number: UA76475C2
Authority: UA; Ukraine
Prior art keywords: nmo; coa reductase; combination; aldosterone; eplerenone
Prior art date: 2001-07-19

Application number

UA2004010388A

Other languages

English (en)

Ukrainian (uk)

Inventor

Bradley T Keller

Ellen G Mcmahon

Original Assignee

Pharmacia Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-19

Filing date

2002-07-18

Publication date

2006-08-15

2002-07-18 Application filed by Pharmacia Corp filed Critical Pharmacia Corp

2006-08-15 Publication of UA76475C2 publication Critical patent/UA76475C2/uk

Links

238000011282 treatment Methods 0.000 title claims abstract description 82
229940123934 Reductase inhibitor Drugs 0.000 title claims description 50
230000001575 pathological effect Effects 0.000 title abstract description 24
238000011321 prophylaxis Methods 0.000 title abstract description 4
210000000748 cardiovascular system Anatomy 0.000 title description 19
239000003112 inhibitor Substances 0.000 claims abstract description 104
108090000854 Oxidoreductases Proteins 0.000 claims description 73
102000004316 Oxidoreductases Human genes 0.000 claims description 73
239000002552 dosage form Substances 0.000 claims description 41
239000003814 drug Substances 0.000 claims description 40
229960001208 eplerenone Drugs 0.000 claims description 36
229940079593 drug Drugs 0.000 claims description 35
JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 claims description 34
239000000203 mixture Substances 0.000 claims description 30
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 18
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 17
229960002965 pravastatin Drugs 0.000 claims description 17
239000008194 pharmaceutical composition Substances 0.000 claims description 16
230000002265 prevention Effects 0.000 claims description 16
239000002253 acid Substances 0.000 claims description 15
150000003839 salts Chemical class 0.000 claims description 15
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 14
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 13
229960005370 atorvastatin Drugs 0.000 claims description 13
229960002797 pitavastatin Drugs 0.000 claims description 13
VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims description 13
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 12
239000000651 prodrug Substances 0.000 claims description 12
229940002612 prodrug Drugs 0.000 claims description 12
206010020772 Hypertension Diseases 0.000 claims description 11
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 11
229960004844 lovastatin Drugs 0.000 claims description 11
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 11
208000010125 myocardial infarction Diseases 0.000 claims description 11
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 11
206010019280 Heart failures Diseases 0.000 claims description 10
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 10
229960000672 rosuvastatin Drugs 0.000 claims description 10
BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims description 10
229960002855 simvastatin Drugs 0.000 claims description 10
201000001320 Atherosclerosis Diseases 0.000 claims description 9
150000002148 esters Chemical class 0.000 claims description 8
ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims description 7
229960003765 fluvastatin Drugs 0.000 claims description 7
SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims description 6
229960005110 cerivastatin Drugs 0.000 claims description 6
150000007513 acids Chemical class 0.000 claims description 5
AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical group C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims description 5
206010002383 Angina Pectoris Diseases 0.000 claims description 4
AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
229950009116 mevastatin Drugs 0.000 claims description 4
BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims description 4
108091007187 Reductases Proteins 0.000 claims description 3
230000002526 effect on cardiovascular system Effects 0.000 claims description 3
206010048554 Endothelial dysfunction Diseases 0.000 claims description 2
208000007536 Thrombosis Diseases 0.000 claims description 2
206010003119 arrhythmia Diseases 0.000 claims description 2
230000006378 damage Effects 0.000 claims description 2
230000008694 endothelial dysfunction Effects 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
230000008085 renal dysfunction Effects 0.000 claims description 2
206010002329 Aneurysm Diseases 0.000 claims 1
206010047295 Ventricular hypertrophy Diseases 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
230000002792 vascular Effects 0.000 claims 1
102000003979 Mineralocorticoid Receptors Human genes 0.000 abstract description 83
108090000375 Mineralocorticoid Receptors Proteins 0.000 abstract description 83
238000000034 method Methods 0.000 abstract description 69
229940044551 receptor antagonist Drugs 0.000 abstract description 62
239000002464 receptor antagonist Substances 0.000 abstract description 62
150000001875 compounds Chemical class 0.000 description 68
238000002648 combination therapy Methods 0.000 description 58
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 45
239000002170 aldosterone antagonist Substances 0.000 description 42
229940083712 aldosterone antagonist Drugs 0.000 description 42
230000000694 effects Effects 0.000 description 32
229960002256 spironolactone Drugs 0.000 description 32
LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 31
-1 steroid compound Chemical class 0.000 description 31
PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 30
PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 30
229960002478 aldosterone Drugs 0.000 description 30
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 29
201000010099 disease Diseases 0.000 description 27
239000005557 antagonist Substances 0.000 description 20
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 19
208000035475 disorder Diseases 0.000 description 18
239000003826 tablet Substances 0.000 description 18
230000001717 pathogenic effect Effects 0.000 description 16
231100000255 pathogenic effect Toxicity 0.000 description 16
239000005541 ACE inhibitor Substances 0.000 description 11
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 11
235000012000 cholesterol Nutrition 0.000 description 11
125000000217 alkyl group Chemical group 0.000 description 10
230000015572 biosynthetic process Effects 0.000 description 10
230000037396 body weight Effects 0.000 description 10
238000005516 engineering process Methods 0.000 description 10
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 10
230000001225 therapeutic effect Effects 0.000 description 10
102000004190 Enzymes Human genes 0.000 description 9
108090000790 Enzymes Proteins 0.000 description 9
230000007423 decrease Effects 0.000 description 9
238000011161 development Methods 0.000 description 9
230000000670 limiting effect Effects 0.000 description 9
210000004185 liver Anatomy 0.000 description 9
238000005259 measurement Methods 0.000 description 9
229940126601 medicinal product Drugs 0.000 description 9
239000004593 Epoxy Substances 0.000 description 8
206010053172 Fatal outcomes Diseases 0.000 description 8
108020001621 Natriuretic Peptide Proteins 0.000 description 8
102000004571 Natriuretic peptide Human genes 0.000 description 8
239000003613 bile acid Substances 0.000 description 8
239000002775 capsule Substances 0.000 description 8
239000000692 natriuretic peptide Substances 0.000 description 8
230000007170 pathology Effects 0.000 description 8
102400000345 Angiotensin-2 Human genes 0.000 description 7
101800000733 Angiotensin-2 Proteins 0.000 description 7
125000002252 acyl group Chemical group 0.000 description 7
229950006323 angiotensin ii Drugs 0.000 description 7
230000009286 beneficial effect Effects 0.000 description 7
210000004369 blood Anatomy 0.000 description 7
239000008280 blood Substances 0.000 description 7
230000029142 excretion Effects 0.000 description 7
239000002395 mineralocorticoid Substances 0.000 description 7
150000003431 steroids Chemical class 0.000 description 7
239000000126 substance Substances 0.000 description 7
238000003786 synthesis reaction Methods 0.000 description 7
238000002560 therapeutic procedure Methods 0.000 description 7
208000035150 Hypercholesterolemia Diseases 0.000 description 6
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 6
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 6
230000008901 benefit Effects 0.000 description 6
208000029078 coronary artery disease Diseases 0.000 description 6
METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 description 6
230000004054 inflammatory process Effects 0.000 description 6
230000003902 lesion Effects 0.000 description 6
230000007246 mechanism Effects 0.000 description 6
210000002381 plasma Anatomy 0.000 description 6
102000005962 receptors Human genes 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
230000036454 renin-angiotensin system Effects 0.000 description 6
239000011734 sodium Substances 0.000 description 6
229920002911 Colestipol Polymers 0.000 description 5
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
206010028980 Neoplasm Diseases 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
238000002586 coronary angiography Methods 0.000 description 5
210000004351 coronary vessel Anatomy 0.000 description 5
230000001419 dependent effect Effects 0.000 description 5
METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 description 5
229960004845 drospirenone Drugs 0.000 description 5
210000000750 endocrine system Anatomy 0.000 description 5
210000003734 kidney Anatomy 0.000 description 5
239000006187 pill Substances 0.000 description 5
239000000902 placebo Substances 0.000 description 5
229940068196 placebo Drugs 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
238000003825 pressing Methods 0.000 description 5
230000008569 process Effects 0.000 description 5
238000011160 research Methods 0.000 description 5
229910052708 sodium Inorganic materials 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
206010007559 Cardiac failure congestive Diseases 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
208000032928 Dyslipidaemia Diseases 0.000 description 4
208000017170 Lipid metabolism disease Diseases 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
102100028255 Renin Human genes 0.000 description 4
108090000783 Renin Proteins 0.000 description 4
208000007814 Unstable Angina Diseases 0.000 description 4
230000009471 action Effects 0.000 description 4
210000001367 artery Anatomy 0.000 description 4
230000000747 cardiac effect Effects 0.000 description 4
210000001715 carotid artery Anatomy 0.000 description 4
239000002934 diuretic Substances 0.000 description 4
239000008187 granular material Substances 0.000 description 4
239000003701 inert diluent Substances 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
239000012907 medicinal substance Substances 0.000 description 4
208000030159 metabolic disease Diseases 0.000 description 4
229960003512 nicotinic acid Drugs 0.000 description 4
239000011664 nicotinic acid Substances 0.000 description 4
235000001968 nicotinic acid Nutrition 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
239000000825 pharmaceutical preparation Substances 0.000 description 4
239000000843 powder Substances 0.000 description 4
239000011347 resin Substances 0.000 description 4
229920005989 resin Polymers 0.000 description 4
238000012360 testing method Methods 0.000 description 4
238000011269 treatment regimen Methods 0.000 description 4
238000002604 ultrasonography Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 description 3
101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 3
URYCWSZWYNTGEX-UHFFFAOYSA-N 4,8,10-trihydroxy-5-methylbenzo[h]chromen-2-one Chemical compound O1C(=O)C=C(O)C2=C1C1=C(O)C=C(O)C=C1C=C2C URYCWSZWYNTGEX-UHFFFAOYSA-N 0.000 description 3
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
208000024827 Alzheimer disease Diseases 0.000 description 3
206010002388 Angina unstable Diseases 0.000 description 3
102100033668 Cartilage matrix protein Human genes 0.000 description 3
229920001268 Cholestyramine Polymers 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
230000004913 activation Effects 0.000 description 3
102000001307 androgen receptors Human genes 0.000 description 3
108010080146 androgen receptors Proteins 0.000 description 3
230000036772 blood pressure Effects 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
229960002604 colestipol Drugs 0.000 description 3
ZADJRRFMOOACHL-WQICJITCSA-N ethyl (e,3s,5r)-7-[4-(4-fluorophenyl)spiro[chromene-2,1'-cyclopentane]-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound C12=CC=CC=C2OC2(CCCC2)C(/C=C/[C@H](O)C[C@H](O)CC(=O)OCC)=C1C1=CC=C(F)C=C1 ZADJRRFMOOACHL-WQICJITCSA-N 0.000 description 3
208000019622 heart disease Diseases 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
239000000543 intermediate Substances 0.000 description 3
201000004332 intermediate coronary syndrome Diseases 0.000 description 3
150000002500 ions Chemical class 0.000 description 3
239000007788 liquid Substances 0.000 description 3
229910021645 metal ion Inorganic materials 0.000 description 3
238000002156 mixing Methods 0.000 description 3
238000000465 moulding Methods 0.000 description 3
210000002346 musculoskeletal system Anatomy 0.000 description 3
229910052700 potassium Inorganic materials 0.000 description 3
239000011591 potassium Substances 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
230000000069 prophylactic effect Effects 0.000 description 3
201000001474 proteinuria Diseases 0.000 description 3
150000003254 radicals Chemical class 0.000 description 3
230000004044 response Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
238000005550 wet granulation Methods 0.000 description 3
102400000344 Angiotensin-1 Human genes 0.000 description 2
101800000734 Angiotensin-1 Proteins 0.000 description 2
102000015427 Angiotensins Human genes 0.000 description 2
108010064733 Angiotensins Proteins 0.000 description 2
206010003445 Ascites Diseases 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
208000024172 Cardiovascular disease Diseases 0.000 description 2
102400000739 Corticotropin Human genes 0.000 description 2
101800000414 Corticotropin Proteins 0.000 description 2
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
108010061435 Enalapril Proteins 0.000 description 2
206010016654 Fibrosis Diseases 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
102000015779 HDL Lipoproteins Human genes 0.000 description 2
108010010234 HDL Lipoproteins Proteins 0.000 description 2
LJIZUXQINHXGAO-ITWZMISCSA-N HR 780 Chemical compound C(\[C@H]1OC(=O)C[C@H](O)C1)=C/C=1C(C(C)C)=NC(C=2C=CC=CC=2)=CC=1C1=CC=C(F)C=C1 LJIZUXQINHXGAO-ITWZMISCSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
206010020880 Hypertrophy Diseases 0.000 description 2
102000007330 LDL Lipoproteins Human genes 0.000 description 2
108010007622 LDL Lipoproteins Proteins 0.000 description 2
208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
XOBKSJJDNFUZPF-UHFFFAOYSA-N Methoxyethane Chemical compound CCOC XOBKSJJDNFUZPF-UHFFFAOYSA-N 0.000 description 2
208000000112 Myalgia Diseases 0.000 description 2
206010028594 Myocardial fibrosis Diseases 0.000 description 2
KUEUWHJGRZKESU-UHFFFAOYSA-N Niceritrol Chemical compound C=1C=CN=CC=1C(=O)OCC(COC(=O)C=1C=NC=CC=1)(COC(=O)C=1C=NC=CC=1)COC(=O)C1=CC=CN=C1 KUEUWHJGRZKESU-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
206010042434 Sudden death Diseases 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
IFIFFBWHLKGTMO-SJIDJMGWSA-N [(1s,3s,4ar,7s,8s,8as)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 IFIFFBWHLKGTMO-SJIDJMGWSA-N 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000002411 adverse Effects 0.000 description 2
150000001325 aldosterones Chemical class 0.000 description 2
229960000528 amlodipine Drugs 0.000 description 2
HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 2
239000003098 androgen Substances 0.000 description 2
ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 2
238000010171 animal model Methods 0.000 description 2
239000003524 antilipemic agent Substances 0.000 description 2
238000013459 approach Methods 0.000 description 2
208000037849 arterial hypertension Diseases 0.000 description 2
230000003143 atherosclerotic effect Effects 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
229950005357 bervastatin Drugs 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
230000036765 blood level Effects 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000011575 calcium Substances 0.000 description 2
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
229960000830 captopril Drugs 0.000 description 2
150000001735 carboxylic acids Chemical class 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
208000019425 cirrhosis of liver Diseases 0.000 description 2
GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 2
239000003433 contraceptive agent Substances 0.000 description 2
230000002254 contraceptive effect Effects 0.000 description 2
229960000258 corticotropin Drugs 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000037213 diet Effects 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
230000001882 diuretic effect Effects 0.000 description 2
238000001647 drug administration Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 2
229960000873 enalapril Drugs 0.000 description 2
239000002702 enteric coating Substances 0.000 description 2
238000009505 enteric coating Methods 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
230000037406 food intake Effects 0.000 description 2
230000006870 function Effects 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
229960003627 gemfibrozil Drugs 0.000 description 2
230000036541 health Effects 0.000 description 2
230000002440 hepatic effect Effects 0.000 description 2
230000013632 homeostatic process Effects 0.000 description 2
230000003054 hormonal effect Effects 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
230000003907 kidney function Effects 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
210000005240 left ventricle Anatomy 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000010534 mechanism of action Effects 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
229960000827 niceritrol Drugs 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
208000033808 peripheral neuropathy Diseases 0.000 description 2
229940127557 pharmaceutical product Drugs 0.000 description 2
230000012495 positive regulation of renal sodium excretion Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
102000003998 progesterone receptors Human genes 0.000 description 2
108090000468 progesterone receptors Proteins 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000000250 revascularization Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000012453 solvate Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000007858 starting material Substances 0.000 description 2
230000003637 steroidlike Effects 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
230000009466 transformation Effects 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
208000019553 vascular disease Diseases 0.000 description 2
230000003313 weakening effect Effects 0.000 description 2
VGSSUFQMXBFFTM-UHFFFAOYSA-N (24R)-24-ethyl-5alpha-cholestane-3beta,5,6beta-triol Natural products C1C(O)C2(O)CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 VGSSUFQMXBFFTM-UHFFFAOYSA-N 0.000 description 1
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
FXAAOALUHHXBSO-ILDUYXDCSA-N (3,3,5-trimethylcyclohexyl) (2s)-5-oxopyrrolidine-2-carboxylate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)[C@H]1NC(=O)CC1 FXAAOALUHHXBSO-ILDUYXDCSA-N 0.000 description 1
VDSBXXDKCUBMQC-HNGSOEQISA-N (4r,6s)-6-[(e)-2-[2-(4-fluoro-3-methylphenyl)-4,4,6,6-tetramethylcyclohexen-1-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C1=C(F)C(C)=CC(C=2CC(C)(C)CC(C)(C)C=2\C=C\[C@H]2OC(=O)C[C@H](O)C2)=C1 VDSBXXDKCUBMQC-HNGSOEQISA-N 0.000 description 1
XJVKVAFYQRWVAJ-MCBHFWOFSA-N (4r,6s)-6-[(e)-2-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound O1C(=O)C[C@H](O)C[C@H]1\C=C\C1=C(C2CC2)N=C(C=CC=C2)C2=C1C1=CC=C(F)C=C1 XJVKVAFYQRWVAJ-MCBHFWOFSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
YPKJAQSYNJIALU-UHFFFAOYSA-N 1,2,3,3a,4,5-hexahydrocyclohepta[c]pyrazole Chemical compound C1=CCCC2CNNC2=C1 YPKJAQSYNJIALU-UHFFFAOYSA-N 0.000 description 1
UDATXMIGEVPXTR-UHFFFAOYSA-N 1,2,4-triazolidine-3,5-dione Chemical class O=C1NNC(=O)N1 UDATXMIGEVPXTR-UHFFFAOYSA-N 0.000 description 1
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
GZHFUHXRIZLFCC-UHFFFAOYSA-N 2,2-dihydroxy-8-(1h-pyrrol-2-ylsulfonyl)oct-7-enoic acid Chemical class OC(=O)C(O)(O)CCCCC=CS(=O)(=O)C1=CC=CN1 GZHFUHXRIZLFCC-UHFFFAOYSA-N 0.000 description 1
IRGLQUMAHASUTG-UHFFFAOYSA-N 2-(3-ethoxycarbonyl-6-methyl-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-9-yl)acetic acid Chemical compound OC(=O)CC1CCC(C)N2C(=O)C(C(=O)OCC)=CN=C21 IRGLQUMAHASUTG-UHFFFAOYSA-N 0.000 description 1
IRGLQUMAHASUTG-IUCAKERBSA-N 2-[(6s,9s)-3-ethoxycarbonyl-6-methyl-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-9-yl]acetic acid Chemical compound OC(=O)C[C@@H]1CC[C@H](C)N2C(=O)C(C(=O)OCC)=CN=C21 IRGLQUMAHASUTG-IUCAKERBSA-N 0.000 description 1
YGPHOWJPGUHNSY-UHFFFAOYSA-N 2-[10-(carboxymethylsulfanyl)decylsulfanyl]acetic acid Chemical compound OC(=O)CSCCCCCCCCCCSCC(O)=O YGPHOWJPGUHNSY-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
NNYJKTFIAUUWRQ-MCBHFWOFSA-N 4-(4-fluorophenyl)-3-[(e)-2-[(2s,4r)-4-hydroxy-6-oxooxan-2-yl]ethenyl]-2-propan-2-ylisoquinolin-1-one Chemical compound C=1C=C(F)C=CC=1C=1C2=CC=CC=C2C(=O)N(C(C)C)C=1\C=C\[C@@H]1C[C@@H](O)CC(=O)O1 NNYJKTFIAUUWRQ-MCBHFWOFSA-N 0.000 description 1
208000004998 Abdominal Pain Diseases 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
DJQOOSBJCLSSEY-UHFFFAOYSA-N Acipimox Chemical compound CC1=CN=C(C(O)=O)C=[N+]1[O-] DJQOOSBJCLSSEY-UHFFFAOYSA-N 0.000 description 1
239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
208000010470 Ageusia Diseases 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
241001044369 Amphion Species 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
229940123413 Angiotensin II antagonist Drugs 0.000 description 1
102000005666 Apolipoprotein A-I Human genes 0.000 description 1
108010059886 Apolipoprotein A-I Proteins 0.000 description 1
101710095342 Apolipoprotein B Proteins 0.000 description 1
102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
200000000007 Arterial disease Diseases 0.000 description 1
206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
101800001288 Atrial natriuretic factor Proteins 0.000 description 1
102400001282 Atrial natriuretic peptide Human genes 0.000 description 1
101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 1
101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 1
101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 1
102000012421 C-Type Natriuretic Peptide Human genes 0.000 description 1
101800000060 C-type natriuretic peptide Proteins 0.000 description 1
206010007556 Cardiac failure acute Diseases 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
208000018152 Cerebral disease Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
208000016998 Conn syndrome Diseases 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
102000004420 Creatine Kinase Human genes 0.000 description 1
108010042126 Creatine kinase Proteins 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
206010013754 Drug withdrawal syndrome Diseases 0.000 description 1
244000078127 Eleusine coracana Species 0.000 description 1
235000013499 Eleusine coracana subsp coracana Nutrition 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
102000002045 Endothelin Human genes 0.000 description 1
108050009340 Endothelin Proteins 0.000 description 1
241000283086 Equidae Species 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
208000010496 Heart Arrest Diseases 0.000 description 1
206010019663 Hepatic failure Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000868422 Homo sapiens Sushi, nidogen and EGF-like domain-containing protein 1 Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
ODCZJZWSXPVLAW-KXCGKLMDSA-N Hymeglusin Chemical compound OC(=O)/C=C(\C)/C=C(C)/C[C@H](C)CCCC[C@H]1OC(=O)[C@@H]1CO ODCZJZWSXPVLAW-KXCGKLMDSA-N 0.000 description 1
208000002682 Hyperkalemia Diseases 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
208000019025 Hypokalemia Diseases 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
208000026139 Memory disease Diseases 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
101500027988 Mus musculus ADGRV1 subunit beta Proteins 0.000 description 1
101100133904 Mus musculus Nrk gene Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000010428 Muscle Weakness Diseases 0.000 description 1
208000021642 Muscular disease Diseases 0.000 description 1
206010028372 Muscular weakness Diseases 0.000 description 1
201000009623 Myopathy Diseases 0.000 description 1
206010057852 Nicotine dependence Diseases 0.000 description 1
235000005294 Nypa Nutrition 0.000 description 1
241000233803 Nypa Species 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
201000007100 Pharyngitis Diseases 0.000 description 1
244000046052 Phaseolus vulgaris Species 0.000 description 1
235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
206010062237 Renal impairment Diseases 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
206010040026 Sensory disturbance Diseases 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
LGJMUZUPVCAVPU-JFBKYFIKSA-N Sitostanol Natural products O[C@@H]1C[C@H]2[C@@](C)([C@@H]3[C@@H]([C@H]4[C@@](C)([C@@H]([C@@H](CC[C@H](C(C)C)CC)C)CC4)CC3)CC2)CC1 LGJMUZUPVCAVPU-JFBKYFIKSA-N 0.000 description 1
206010041277 Sodium retention Diseases 0.000 description 1
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
241000282887 Suidae Species 0.000 description 1
102100032853 Sushi, nidogen and EGF-like domain-containing protein 1 Human genes 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
208000025569 Tobacco Use disease Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
102000003929 Transaminases Human genes 0.000 description 1
108090000340 Transaminases Proteins 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
102000002852 Vasopressins Human genes 0.000 description 1
108010004977 Vasopressins Proteins 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
NPDFVGFXQSJBAA-CKLJVHAJSA-N [(1s,7s,8s,8as)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-6-oxo-2,7,8,8a-tetrahydro-1h-naphthalen-1-yl] 2,2-dimethylbutanoate Chemical compound C([C@@H]1[C@H](C)C(=O)C=C2C=C(C)C[C@@H]([C@@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 NPDFVGFXQSJBAA-CKLJVHAJSA-N 0.000 description 1
NABZXASCLFSKLF-UHFFFAOYSA-N [1,2]oxazolo[4,3-b]pyridine Chemical compound C1=CC=NC2=CON=C21 NABZXASCLFSKLF-UHFFFAOYSA-N 0.000 description 1
230000009102 absorption Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
229960003526 acipimox Drugs 0.000 description 1
206010000891 acute myocardial infarction Diseases 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
235000019666 ageusia Nutrition 0.000 description 1
229940092229 aldactone Drugs 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
238000002583 angiography Methods 0.000 description 1
239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
229920006318 anionic polymer Polymers 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
230000001864 anti-aldosterone effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
208000028922 artery disease Diseases 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
206010003549 asthenia Diseases 0.000 description 1
239000002585 base Substances 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
150000001562 benzopyrans Chemical class 0.000 description 1
LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
102000030904 bile acid binding Human genes 0.000 description 1
108091022863 bile acid binding Proteins 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000035587 bioadhesion Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
150000001638 boron Chemical class 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000013155 cardiography Methods 0.000 description 1
NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
229960002023 chloroprocaine Drugs 0.000 description 1
239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 1
150000001840 cholesterol esters Chemical class 0.000 description 1
229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
208000013116 chronic cough Diseases 0.000 description 1
230000002060 circadian Effects 0.000 description 1
230000004087 circulation Effects 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
229960001214 clofibrate Drugs 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000008139 complexing agent Substances 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
208000026758 coronary atherosclerosis Diseases 0.000 description 1
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
229950002753 crilvastatin Drugs 0.000 description 1
239000013078 crystal Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
231100000856 decreased creatinine clearance Toxicity 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
229940043237 diethanolamine Drugs 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
FXHKSTYWSZZOBF-NTEVMMBTSA-L disodium;(3s)-4-[2-[1-(4-fluorophenyl)-3-propan-2-ylindol-2-yl]ethynyl-oxidophosphoryl]-3-hydroxybutanoate Chemical compound [Na+].[Na+].C12=CC=CC=C2C(C(C)C)=C(C#CP([O-])(=O)C[C@@H](O)CC([O-])=O)N1C1=CC=C(F)C=C1 FXHKSTYWSZZOBF-NTEVMMBTSA-L 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
210000001038 distal kidney tubule Anatomy 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
201000006549 dyspepsia Diseases 0.000 description 1
238000002565 electrocardiography Methods 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
230000008753 endothelial function Effects 0.000 description 1
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229960002568 ethinylestradiol Drugs 0.000 description 1
229940012017 ethylenediamine Drugs 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
230000003631 expected effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
206010016766 flatulence Diseases 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
229950000806 glenvastatin Drugs 0.000 description 1
230000024924 glomerular filtration Effects 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
201000000079 gynecomastia Diseases 0.000 description 1
230000003760 hair shine Effects 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011221 initial treatment Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000005977 kidney dysfunction Effects 0.000 description 1
238000009533 lab test Methods 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
150000002596 lactones Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
230000005976 liver dysfunction Effects 0.000 description 1
208000007903 liver failure Diseases 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
230000003295 lusitropic effect Effects 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000002595 magnetic resonance imaging Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
230000007257 malfunction Effects 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
238000009607 mammography Methods 0.000 description 1
235000013310 margarine Nutrition 0.000 description 1
239000003264 margarine Substances 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
230000006984 memory degeneration Effects 0.000 description 1
208000023060 memory loss Diseases 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical group [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
244000005700 microbiome Species 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
150000004712 monophosphates Chemical class 0.000 description 1
208000013465 muscle pain Diseases 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
230000000956 myotropic effect Effects 0.000 description 1
101150109980 napA gene Proteins 0.000 description 1
230000001452 natriuretic effect Effects 0.000 description 1
230000004903 negative regulation of intestinal cholesterol absorption Effects 0.000 description 1
HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
208000004235 neutropenia Diseases 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
208000024896 potassium deficiency disease Diseases 0.000 description 1
229940070017 potassium supplement Drugs 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
229960001495 pravastatin sodium Drugs 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
208000013846 primary aldosteronism Diseases 0.000 description 1
201000009395 primary hyperaldosteronism Diseases 0.000 description 1
FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
229960003912 probucol Drugs 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000000757 progestagenic effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
150000008518 pyridopyrimidines Chemical class 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
235000002079 ragi Nutrition 0.000 description 1
206010037844 rash Diseases 0.000 description 1
230000009103 reabsorption Effects 0.000 description 1
230000029865 regulation of blood pressure Effects 0.000 description 1
230000002207 retinal effect Effects 0.000 description 1
230000033764 rhythmic process Effects 0.000 description 1
210000003079 salivary gland Anatomy 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
201000009890 sinusitis Diseases 0.000 description 1
231100000046 skin rash Toxicity 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
RGEBGDYYHAFODH-DHMAKVBVSA-M sodium;(e,3r,5s)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate Chemical compound [Na+].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O RGEBGDYYHAFODH-DHMAKVBVSA-M 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
241000894007 species Species 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
125000003003 spiro group Chemical group 0.000 description 1
239000003270 steroid hormone Substances 0.000 description 1
LGJMUZUPVCAVPU-HRJGVYIJSA-N stigmastanol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]2(C)CC1 LGJMUZUPVCAVPU-HRJGVYIJSA-N 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
210000000106 sweat gland Anatomy 0.000 description 1
210000002820 sympathetic nervous system Anatomy 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
238000004448 titration Methods 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000032258 transport Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
238000002562 urinalysis Methods 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
238000005353 urine analysis Methods 0.000 description 1
230000003966 vascular damage Effects 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
229960003726 vasopressin Drugs 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229930188494 zaragozic acid Natural products 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229960002769 zofenopril Drugs 0.000 description 1
IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Rheumatology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychiatry (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Addiction (AREA)
Oncology (AREA)
Transplantation (AREA)
Communicable Diseases (AREA)
Child & Adolescent Psychology (AREA)

UA2004010388A 2001-07-19 2002-07-18 Combination of eplerenon and hmg co-a reductase inhibitor and its use for treatment and/or prophylaxis of pathologic condition in cardiovascular system UA76475C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US30633601P	2001-07-19	2001-07-19
PCT/US2002/022896 WO2003007993A1 (en)	2001-07-19	2002-07-18	Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor

Publications (1)

Publication Number	Publication Date
UA76475C2 true UA76475C2 (en)	2006-08-15

Family

ID=23184836

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2004010388A UA76475C2 (en)	2001-07-19	2002-07-18	Combination of eplerenon and hmg co-a reductase inhibitor and its use for treatment and/or prophylaxis of pathologic condition in cardiovascular system

Country Status (26)

Country	Link
US (2)	US20030149010A1 (de)
EP (1)	EP1406660B1 (de)
JP (1)	JP2004537553A (de)
KR (1)	KR20040023660A (de)
CN (1)	CN1537019A (de)
AP (1)	AP2004002951A0 (de)
AT (1)	ATE363917T1 (de)
BR (1)	BR0211274A (de)
CA (1)	CA2452678A1 (de)
CO (1)	CO5550464A2 (de)
DE (1)	DE60220522T2 (de)
EA (1)	EA200400029A1 (de)
EC (1)	ECSP044950A (de)
ES (1)	ES2286270T3 (de)
GE (1)	GEP20063811B (de)
IL (1)	IL159588A0 (de)
IS (1)	IS7093A (de)
MA (1)	MA27050A1 (de)
MX (1)	MXPA04000586A (de)
NO (1)	NO20040211L (de)
OA (1)	OA12983A (de)
PL (1)	PL367417A1 (de)
TN (1)	TNSN04001A1 (de)
UA (1)	UA76475C2 (de)
WO (1)	WO2003007993A1 (de)
ZA (1)	ZA200400288B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2003901812A0 (en) *	2003-04-15	2003-05-01	Vital Health Sciences Pty Ltd	Phosphates of secondary alcohols
US8026237B2 (en)	2004-07-30	2011-09-27	Exelixis, Inc.	Pyrrole derivatives as pharmaceutical agents
US20090162316A1 (en) *	2005-07-05	2009-06-25	Harvard University	Liver targeted conjugates
CN1310941C (zh) *	2005-07-13	2007-04-18	南京大学	依普利酮的合成方法
SG166829A1 (en) *	2005-11-08	2010-12-29	Ranbaxy Lab Ltd	Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
GB0600967D0 (en) *	2006-01-18	2006-03-01	Imp Innovations Ltd	Methods
WO2007106862A2 (en) *	2006-03-14	2007-09-20	Kinemed, Inc.	The use of statins to stimulate neurogenesis
WO2008021666A2 (en) *	2006-08-18	2008-02-21	Morton Grove Pharmaceuticals, Inc.	Stable liquid levetiracetam compositions and methods
FR2917975B1 (fr) *	2007-06-26	2009-10-16	Ceva Sante Animale Sa	Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains
EP2135607A1 (de)	2008-06-18	2009-12-23	Pharnext	Kombination aus Pilocarpin und Methimazol zur Behandlung der Charcot-Marie-Tooth Krankheit und verwandten Erkrankungen
EP2367554A4 (de) *	2008-11-26	2020-03-25	Satiogen Pharmaceuticals, Inc.	Gallensäurerückflusshemmer zur behandlung von adipositas und diabetes
US9387206B2 (en)	2009-11-03	2016-07-12	Pharnext	Therapeutic approaches for treating Alzheimer's disease
EP2322163A1 (de) *	2009-11-03	2011-05-18	Pharnext	Neue therapeutische Ansätze zur Behandlung von Alzheimer-Krankheit
NZ600123A (en) *	2009-11-30	2015-04-24	Aptalis Pharmatech Inc	Compressible-coated pharmaceutical compositions and tablets and methods of manufacture
EP3593802A3 (de)	2010-05-26	2020-03-25	Satiogen Pharmaceuticals, Inc.	Gallensäurerückflusshemmer zur behandlung von diabetes, adipositas und entzündlichen magen-darm-erkrankungen
US9107983B2 (en)	2010-10-27	2015-08-18	Warsaw Orthopedic, Inc.	Osteoconductive matrices comprising statins
US8877221B2 (en)	2010-10-27	2014-11-04	Warsaw Orthopedic, Inc.	Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US10010515B2 (en)	2011-03-01	2018-07-03	Pharnext	Therapeutic approaches for treating Parkinson's disease
SI2560631T1 (sl)	2011-03-01	2014-06-30	Pharnext	Na baklofenu in akamprosatu temeljeäśa terapija nevroloĺ kih nepravilnosti
US9248111B2 (en)	2011-03-01	2016-02-02	Pharnext	Therapeutic approaches for treating parkinson's disease
US9241933B2 (en)	2011-03-01	2016-01-26	Pharnext	Compositions for treating amyotrophic lateral sclerosis
DE102011015142A1 (de) *	2011-03-17	2012-09-20	Eberhard-Karls-Universität Tübingen Universitätsklinikum	Agens zur Prophylaxe und Behandlung altersassoziierter Krankheiten und Störungen sowie zur Verlängerung der Lebensdauer
US9308190B2 (en)	2011-06-06	2016-04-12	Warsaw Orthopedic, Inc.	Methods and compositions to enhance bone growth comprising a statin
KR102051031B1 (ko)	2011-10-28	2019-12-02	루메나 파마수티컬즈, 인코포레이티드	고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
BR112014010223B8 (pt)	2011-10-28	2021-02-23	Lumena Pharmaceuticals Llc	uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica
EP2968230A2 (de)	2013-03-15	2016-01-20	Lumena Pharmaceuticals, Inc.	Gallensäurerückflusshemmer zur behandlung von primär sklerosierender cholongitis und entzündlichen darmerkrankungen
KR20160003664A (ko)	2013-03-15	2016-01-11	루메나 파마수티컬즈, 인코포레이티드	바렛 식도 및 위식도 역류 질환 치료용 담즙산 재순환 억제제
MX2016009060A (es) *	2014-01-10	2016-09-09	Critical Care Diagnostics Inc	Metodos y sistemas para determinar el riesgo de falla cardiaca.
CA3129826A1 (en)	2019-02-12	2020-08-20	Mirum Pharmaceuticals, Inc.	Methods for treating cholestasis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100431038B1 (ko) *	1995-07-17	2004-05-12	워너-램버트 캄파니 엘엘씨	결정질[ｒ-(ｒ,ｒ)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1ｈ-피롤-1-헵탄산 헤미 칼슘염 (아토르바스타틴)
ID23687A (id) *	1997-04-18	2000-05-11	Searle & Co	Metode penggunaan penghambat siklooksigenase-2 dalam pencegahan penyakit kardiovaskuler
GT199800126A (es) *	1997-08-29	2000-01-29		Terapia de combinacion.
US6638937B2 (en) *	1998-07-06	2003-10-28	Bristol-Myers Squibb Co.	Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
UA74141C2 (uk) *	1998-12-09	2005-11-15	Дж.Д. Сірл Енд Ко.	Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
AU4348200A (en) *	1999-04-19	2000-11-02	Regents Of The University Of Michigan, The	Compositions and methods for increasing the bioavailability of lactone ring containing drugs

2002
- 2002-07-18 AT AT02756521T patent/ATE363917T1/de not_active IP Right Cessation
- 2002-07-18 DE DE60220522T patent/DE60220522T2/de not_active Expired - Fee Related
- 2002-07-18 JP JP2003513598A patent/JP2004537553A/ja active Pending
- 2002-07-18 OA OA1200400005A patent/OA12983A/en unknown
- 2002-07-18 IL IL15958802A patent/IL159588A0/xx unknown
- 2002-07-18 KR KR10-2004-7000846A patent/KR20040023660A/ko not_active Ceased
- 2002-07-18 PL PL02367417A patent/PL367417A1/xx not_active Application Discontinuation
- 2002-07-18 MX MXPA04000586A patent/MXPA04000586A/es active IP Right Grant
- 2002-07-18 AP APAP/P/2004/002951A patent/AP2004002951A0/en unknown
- 2002-07-18 EP EP02756521A patent/EP1406660B1/de not_active Expired - Lifetime
- 2002-07-18 CN CNA028145577A patent/CN1537019A/zh active Pending
- 2002-07-18 EA EA200400029A patent/EA200400029A1/ru unknown
- 2002-07-18 US US10/198,475 patent/US20030149010A1/en not_active Abandoned
- 2002-07-18 WO PCT/US2002/022896 patent/WO2003007993A1/en not_active Ceased
- 2002-07-18 ES ES02756521T patent/ES2286270T3/es not_active Expired - Lifetime
- 2002-07-18 BR BR0211274-4A patent/BR0211274A/pt not_active IP Right Cessation
- 2002-07-18 CA CA002452678A patent/CA2452678A1/en not_active Abandoned
- 2002-07-18 GE GE5410A patent/GEP20063811B/en unknown
- 2002-07-18 UA UA2004010388A patent/UA76475C2/uk unknown
2003
- 2003-12-23 IS IS7093A patent/IS7093A/is unknown
2004
- 2004-01-06 TN TNP2004000001A patent/TNSN04001A1/fr unknown
- 2004-01-14 ZA ZA2004/00288A patent/ZA200400288B/en unknown
- 2004-01-15 MA MA27479A patent/MA27050A1/fr unknown
- 2004-01-16 NO NO20040211A patent/NO20040211L/no not_active Application Discontinuation
- 2004-01-19 CO CO04002848A patent/CO5550464A2/es not_active Application Discontinuation
- 2004-01-19 EC EC2004004950A patent/ECSP044950A/es unknown
2005
- 2005-08-18 US US11/206,499 patent/US20060003975A1/en not_active Abandoned

Also Published As

Publication number	Publication date
OA12983A (en)	2006-10-13
IL159588A0 (en)	2004-06-01
EA200400029A1 (ru)	2004-08-26
CN1537019A (zh)	2004-10-13
EP1406660B1 (de)	2007-06-06
US20060003975A1 (en)	2006-01-05
NO20040211L (no)	2004-03-16
CO5550464A2 (es)	2005-08-31
EP1406660A1 (de)	2004-04-14
MA27050A1 (fr)	2004-12-20
CA2452678A1 (en)	2003-01-30
BR0211274A (pt)	2004-08-03
KR20040023660A (ko)	2004-03-18
ECSP044950A (es)	2004-02-26
PL367417A1 (en)	2005-02-21
GEP20063811B (en)	2006-05-10
TNSN04001A1 (fr)	2006-06-01
ZA200400288B (en)	2005-06-29
ES2286270T3 (es)	2007-12-01
JP2004537553A (ja)	2004-12-16
DE60220522T2 (de)	2007-09-27
ATE363917T1 (de)	2007-06-15
WO2003007993A1 (en)	2003-01-30
AP2004002951A0 (en)	2004-03-31
MXPA04000586A (es)	2004-04-20
IS7093A (is)	2003-12-23
US20030149010A1 (en)	2003-08-07
DE60220522D1 (de)	2007-07-19

Publication	Publication Date	Title
EP1406660B1 (de)	2007-06-06	Kombination von einem aldosterone rezeptor antagonisten und einem hmg coa reduktase hemmer
EP1140187B1 (de)	2003-09-03	Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen
JP7134092B2 (ja)	2022-09-09	胆汁うっ滞性及び線維性の疾患の処置方法
WO2007106708A2 (en)	2007-09-20	Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
US20030119786A1 (en)	2003-06-26	Combinations for the treatment of immunoinflammatory disorders
US20040266743A1 (en)	2004-12-30	Combination of an aldosterone receptor antagonist and a renin inhibitor
CN117042770A (zh)	2023-11-10	用于患有高脂血症或混合性血脂异常的他汀类不耐受患者的奥比塞曲匹与依折麦布的组合治疗
US20040192584A1 (en)	2004-09-30	Combination of an aldosterone receptor antagonist and a neutral endopeptidase inhibitor
JP2005532338A5 (de)	2006-07-20
JPH04243839A (ja)	1992-08-31	ＨＭＧ　ＣｏＡリダクターゼインヒビター含有医薬
US20100204190A1 (en)	2010-08-12	New combinations
JPWO2005102381A1 (ja)	2008-03-06	カテプシンｋ阻害薬およびｐｔｈ類を併用することを特徴とする骨密度増加剤
SK14102002A3 (sk)	2003-06-03	Farmaceutické kombinácie a formulácie, ktoré obsahujú betablokátor a činidlo, ktoré znižuje hladinu cholesterolu, ich použitie a "kit of parts", ktorý ich obsahuje
JPH08503451A (ja)	1996-04-16	癌治療のモダリティーとしての３‐ヒドロキシ‐３‐メチルグルタリルＣｏＡレダクターゼ阻害剤の使用
AU2003222009A1 (en)	2003-10-08	Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative
KR19980702099A (ko)	1998-07-15	심장혈관질환의 치료를 위한 안지오텐신 전환 효소 억제제와 부작용-감소된 양의 알도스테론 길항제의 조합 치료요법
TW200803868A (en)	2008-01-16	Novel method for treating hyperlipidemia
JP4454985B2 (ja)	2010-04-21	血液脂質を低下させるための医薬組成物
CZ20024181A3 (cs)	2003-04-16	Farmaceutické prostředky obsahující betablokátor
AU2002322526A1 (en)	2003-03-03	Combination of an aldosterone receptor antagonist and an HMG CoA reductase inhibitor
JPH1081633A (ja)	1998-03-31	医薬組成物
WO2023225163A1 (en)	2023-11-23	Methods of treating focal segmental glomerulosclerosis with atrasentan
SK11092001A3 (sk)	2001-12-03	Kombinácia vzájomne nereagujúcich liečiv obsahujúca inhibítor hmg-coa reduktázy a inhibítor, induktor alebo substrát p450 izoenzýmu 3a4
ZA200105838B (en)	2002-10-16	Drug combinations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-YL] (3R,5S) -3,5-dihydroxyhept-6-enoic acid and an inhibitor inducer or substrate of P450 isoenzyme 3A4.
HK1066480A (en)	2005-03-24	Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor